Logotype for Shattuck Labs Inc

Shattuck Labs (STTK) investor relations material

Shattuck Labs The United European Gastroenterology (UEG) Congress UEG Week 2025 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Shattuck Labs Inc
The United European Gastroenterology (UEG) Congress UEG Week 2025 summary8 Oct, 2025

Key scientific insights

  • DR3 is a stable, broadly expressed receptor in IBD, making it a promising therapeutic target compared to the transiently expressed TL1A ligand.

  • Blocking DR3 may offer superior efficacy and reduced immunogenicity versus TL1A blockade, as DR3 targeting avoids immune complex formation that drives anti-drug antibody responses.

  • The DR3 blocking antibody (SL325) is designed for high affinity and lacks Fc gamma receptor binding, minimizing off-target effects and residual agonism.

  • Preclinical studies confirmed SL325 does not induce T cell proliferation or cytokine release, supporting its antagonist profile.

  • No other disclosed DR3 antagonist programs are known, with technical challenges limiting competition.

Clinical development and strategy

  • Phase 1 trials for the DR3 antibody are ongoing, with completion expected in the first half of next year.

  • Plans are in place to move directly into multiple placebo-controlled phase 2 trials, including at least one in IBD.

  • Comparative efficacy and immunogenicity versus TL1A antibodies will be key endpoints in upcoming studies.

  • Data from these trials are anticipated in 2026.

  • Study design aims to facilitate cross-trial comparisons with existing TL1A therapies.

Market and indication landscape

  • TL1A/DR3 pathway is implicated in IBD, asthma, psoriatic arthritis, psoriasis, rheumatoid arthritis, and primary biliary cirrhosis.

  • DR3 targeting may be especially effective in diseases with persistent antigen exposure, such as IBD and RA, compared to relapsing-remitting diseases like asthma.

  • Major pharmaceutical companies are pursuing TL1A blockade in multiple indications, but DR3 antagonism may offer differentiation.

  • The antibody's broad potential across autoimmune and fibrotic diseases increases its clinical and commercial attractiveness.

  • No current competitors have advanced DR3 antagonists to clinical disclosure, suggesting a first-mover advantage.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Shattuck Labs earnings date

Logotype for Shattuck Labs Inc
Q3 20257 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Shattuck Labs earnings date

Logotype for Shattuck Labs Inc
Q3 20257 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Shattuck Labs Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer and autoimmune diseases. The company leverages its proprietary Agonist Redirected Checkpoint (ARC) platform to create biologic therapies that enhance the body's immune response. Shattuck Labs' technology is designed to modulate immune pathways, potentially improving outcomes for patients with challenging conditions. The company is involved in research and development efforts, advancing its immunotherapy candidates through clinical trials. The company is headquartered in Durham, North Carolina, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage